European life sciences investment firm, Medicxi, has launched a $400 million ‘Medicxi IV’ to continue supporting “asset-focused” biotechs that are delivering transformative therapies for patients.
Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full-drug development continuum. It is one of the largest platforms in Europe for scientific entrepreneurs and drug hunters, with a core team of 35 dedicated investment and drug development professionals.
The firm invests in early and late-stage therapeutics with a product vision that can fulfil a clear unmet medical need. Among its current 43 portfolio companies are some from Switzerland, including Swiss biotech startups such as ObsEVa, Molecular Partners and GlycoVaxyn.